PMID- 27623682
OWN - NLM
STAT- Publisher
LR  - 20220321
IS  - 2567-689X (Electronic)
IS  - 0340-6245 (Linking)
VI  - 116
IP  - Suppl. 2
DP  - 2016 Sep 28
TI  - Spotlight on advances in VTE management: CALLISTO and EINSTEIN CHOICE.
PG  - S24-S32
AB  - Venous thromboembolism (VTE) is associated with numerous complications and high 
      mortality rates. Patients with cancer are at high risk of developing 
      cancer-associated thrombosis (CAT), and VTE recurrence is common. Evidence 
      supporting use of non-vitamin K antagonist (VKA) oral anticoagulants (NOACs) in 
      patients with cancer is lacking - direct comparisons between NOACs and 
      low-molecular-weight heparin (LMWH) are needed, along with patient-reported 
      outcomes. Cancer Associated thrombosis - expLoring soLutions for patients through 
      Treatment and Prevention with RivarOxaban (CALLISTO) is an international research 
      programme exploring the potential of the direct, oral factor Xa inhibitor 
      rivaroxaban for the prevention and treatment of CAT, supplementing existing data 
      from EINSTEIN DVT and EINSTEIN PE. Here, we focus on four CALLISTO studies: A 
      Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism 
      Prophylaxis in Ambulatory Cancer Participants receiving Chemotherapy (CASSINI), 
      Anticoagulation Therapy in SELECTeD Cancer Patients at Risk of Recurrence of 
      Venous Thromboembolism (SELECT-D), Rivaroxaban in the Treatment of Venous 
      Thromboembolism in Cancer Patients - a Randomized Phase III Study (CONKO-011) and 
      a database analysis. Optimal anticoagulation duration for VTE treatment has 
      always been unclear. Following favourable results for rivaroxaban 20 mg 
      once-daily (Q. D.) for secondary VTE prevention (EINSTEIN EXT), EINSTEIN CHOICE 
      is assessing rivaroxaban safety and (20 mg Q. D. or 10 mg Q. D.) vs 
      acetylsalicylic acid (ASA), and will investigate whether an alternative 
      rivaroxaban dose (10 mg Q. D.) could offer long-term VTE protection. It is 
      anticipated that results from these studies will provide important answers and 
      expand upon current evidence for rivaroxaban in VTE management.
FAU - Bach, Miriam
AU  - Bach M
FAU - Bauersachs, Rupert
AU  - Bauersachs R
AD  - Rupert Bauersachs, Klinikum Darmstadt GmbH, Department of Vascular Medicine, 
      Grafenstrasse 9, 64283 Darmstadt, Germany, Tel.: +49 6151 / 107 4401, E-mail: 
      bauersachs@em.uni-frankfurt.de.
LA  - eng
PT  - Journal Article
DEP - 20160914
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
OTO - NOTNLM
OT  - Cancer-associated thrombosis
OT  - rivaroxaban
OT  - thromboprophylaxis
OT  - venous thromboembolism
EDAT- 2016/09/15 06:00
MHDA- 2016/09/15 06:00
CRDT- 2016/09/15 06:00
PHST- 2016/06/29 00:00 [received]
PHST- 2016/07/10 00:00 [accepted]
PHST- 2016/09/15 06:00 [entrez]
PHST- 2016/09/15 06:00 [pubmed]
PHST- 2016/09/15 06:00 [medline]
AID - 16-06-0486 [pii]
AID - 10.1160/TH16-06-0486 [doi]
PST - ppublish
SO  - Thromb Haemost. 2016 Sep 28;116(Suppl. 2):S24-S32. doi: 10.1160/TH16-06-0486. 
      Epub 2016 Sep 14.